SECURITIES AND EXCHANGE COMMISSION

Transcript

1. #1prepared remarks

   EX-99.1 2 a2026q3exhibit991.htm EX-99.1

2. #2prepared remarks

   Exhibit 99.1 | | | | | | | | | Media contact: media-relations@its.jnj.com | | Investor contact: investor-relations@its.jnj.com |

3. #3Joaquin Duato · Chairman and Chief Executive Officer

   Johnson & Johnson’s strong third-quarter performance and increased sequential growth reflect the accelerating momentum of our focused portfolio,

4. #4prepared remarks

   1 Non-GAAP financial measure; refer to reconciliations of non-GAAP financial measures included in accompanying schedules 2 Excludes the impact of translational currency 3 Excludes the net impact of acquisitions and divestitures and translational currency 4 Excludes intangible amortization expense and special items 5 Non-GAAP financial measure; defined as cash flow from operating activities, less additions to property, plant and equipment. Cash flow from operations, the most directly comparable GAAP financial measure, will be included in subsequent SEC filings. 6 Third-quarter YTD 2026 is estimated as of October 13, 2026 Note: values may have been rounded

5. #5prepared remarks

   Regional sales results | | | | | | | | | | | | | | | | | | | | | Q3 | | | | % Change | | ($ in Millions) | 2026 | 2025 | Reported | Operational 1,2 | Currency | Adjusted Operational 1,3 | U.S. | $14,959 | $13,708 | 9.1 | % | 9.1 | — | | 9.1 | International | 10,440 | | 10,285 | | 1.5 | | 1.8 | (0.3) | | 1.9 | Worldwide | $25,399 | $23,993 | 5.9 | % | 6.0 | (0.1) | | 6.1 |

6. #6prepared remarks

   1 Non-GAAP financial measure; refer to reconciliations of non-GAAP financial measures included in accompanying schedules 2 Excludes the impact of translational currency 3 Excludes the net impact of acquisitions and divestitures and translational currency Note: values may have been rounded

7. #7prepared remarks

   Segment sales results | | | | | | | | | | | | | | | | | | | | | Q3 | | | | % Change | | | ($ in Millions) | 2026 | 2025 | Reported | Operational 1,2 | Currency | Adjusted Operational 1,3 | Innovative Medicine | $16,757 | $15,563 | 7.7 | % | 7.9 | (0.2) | | 8.0 | MedTech | 8,642 | | 8,430 | | 2.5 | | 2.5 | 0.0 | | 2.5 | Worldwide | $25,399 | $23,993 | 5.9 | % | 6.0 | (0.1) | | 6.1 |

8. #8prepared remarks

   1 Non-GAAP financial measure; refer to reconciliations of non-GAAP financial measures included in accompanying schedules 2 Excludes the impact of translational currency 3 Excludes the net impact of acquisitions and divestitures and translational currency Note: values may have been rounded

9. #9prepared remarks

   Third-Quarter 2026 segment commentary: Operational sales* reflected below excludes the impact of translational currency. Innovative Medicine Innovative Medicine worldwide operational sales grew 7.9%*, with divestitures negatively impacting growth by 10 basis points. Growth was primarily driven by TREMFYA and new products within Other in Immunology, DARZALEX, CARVYKTI, TECVAYLI, RYBREVANT/LAZCLUZE, and ERLEADA in Oncology, and SPRAVATO and CAPLYTA in Neuroscience. Growth was partially offset by STELARA (an approximate 690 basis points impact), SIMPONI/SIMPONI ARIA, and REMICADE in Immunology, as well as OPSUMIT/OPSYNVI in Pulmonary Hypertension, and IMBRUVICA in Oncology. MedTech MedTech worldwide operational sales grew 2.5%*. Growth was primarily driven by electrophysiology products and Shockwave in Cardiovascular, contact lenses in Vision, as well as trauma in Orthopaedics.

10. #10prepared remarks

    Full-year 2026 guidance: Johnson & Johnson does not provide GAAP financial measures on a forward-looking basis because the company is unable to predict with reasonable certainty the ultimate outcome of legal proceedings, unusual gains and losses, acquisition-related expenses, and purchase accounting fair value adjustments without unreasonable effort. These items are uncertain, depend on various factors, and could be material to Johnson & Johnson's results computed in accordance with GAAP. | | | | | | | | | ($ in Billions, except EPS) | October 2026 | July 29, 2026 | Adjusted Operational Sales 1,2 Change vs. Prior Year / Mid-point | 6.4% – 6.8% / 6.6% | 6.2% – 6.8% / 6.5% | Operational Sales 2 / Mid-point Change vs. Prior Year / Mid-point | $100.5B – $100.9B /$100.7B 6.7% – 7.1% / 6.9%

11. #11prepared remarks

    | $100.3B – $100.9B / $100.6B 6.5% – 7.1% / 6.8%

12. #12prepared remarks

    | Estimated Reported Sales 3 / Mid-point Change vs. Prior Year / Mid-point | $101.0B – $101.4B / $101.2B 7.2% – 7.6% / 7.4%

13. #13prepared remarks

    | $100.8B – $101.4B / $101.1B 7.0% – 7.6% / 7.3%

14. #14prepared remarks

    | Adjusted Operational EPS (Diluted) 2,4 / Mid-point Change vs. Prior Year / Mid-point | $10.95 – $11.05 / $11.00 1.5% – 2.4% / 2.0%

15. #15prepared remarks

    | $10.86 – $11.01 / $10.94 0.7% – 2.1% / 1.4%

16. #16prepared remarks

    | Adjusted EPS (Diluted) 3,4 / Mid-point Change vs. Prior Year / Mid-point | $11.05 – $11.15 / $11.10 2.4% – 3.3% / 2.9%

17. #17prepared remarks

    | $10.96 – $11.11 / $11.04 1.6% – 3.0% / 2.3%

18. #18prepared remarks

    1 Non-GAAP financial measure; excludes the net impact of acquisitions and divestitures 2 Non-GAAP financial measure; excludes the impact of translational currency 3 Calculated using Euro Average Rate: October 2026 = $1.15 and July 2026 = $1.15 (Illustrative purposes only) 4 Non-GAAP financial measure; excludes intangible amortization expense and special items Note: percentages may have been rounded Other modeling considerations will be provided on the webcast . Notable announcements in the quarter: The information contained in this section should be read together with Johnson & Johnson’s other disclosures filed with the Securities and Exchange Commission, including its Current Reports on Form 8-K, Quarterly Reports on Form 10-Q and Annual Reports on Form 10-K. Copies of these filings are available online at www.sec.gov , www.jnj.com or on request from Johnson & Johnson. The reader is also encouraged to review all other news releases and information available in the Investor Relations section of the company’s website at Investor News , as well as Innovative Medicine Newsroom , MedTech News & Events , and www.factsabouttalc.com .

19. #19prepared remarks

    | | | | | | | | | | | | Regulatory | Johnson & Johnson Receives CE Marking for ACUVUE OASYS MAX Reusable Contact Lenses 1 | Press Release | | | FDA approves IMAAVY® (nipocalimab-aahu) as first-ever treatment for warm autoimmune hemolytic anemia (wAIHA), representing a landmark advancement for patients | Press Release | | | Johnson & Johnson's RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) receives U.S. FDA Priority Review as potential first-in-class EGFR- and MET-targeted subcutaneous treatment for advanced head and neck cancer | Press Release | | | Johnson & Johnson Receives FDA Market Authorization in the U.S. for its OTTAVA™ Robotic Surgical System | Press Release | | | Johnson & Johnson Announces MONARCH™ QUEST 3, Advancing the Latest in Robotically-Assisted Bronchoscopy | Press Release | |

20. #20prepared remarks

    | | | | | | | | | | | | Data Releases | New Johnson & Johnson ICOTYDE® (icotrokinra) long-term data demonstrate robust 2- year results in the treatment of adults and adolescents with plaque psoriasis 1 | Press Release | | | Johnson & Johnson announces new ICOTYDE™ (icotrokinra) data in difficult-to-treat plaque psoriasis with proven durability through 2-years, affirming its use as a powerful first line systemic therapy 1 | Press Release | | | Johnson & Johnson presents new data reinforcing sustained disease control and improved daily function achieved with IMAAVY® (nipocalimab-aahu) in generalized myasthenia gravis (gMG) | Press Release | | | Johnson & Johnson announces TREMFYA® (guselkumab) is the first and only IL-23 inhibitor to show significant improvement in spinal pain and stiffness in landmark axial psoriatic arthritis (PsA) study | Press Release | | | Single infusion of CARVYKTI® (ciltacabtagene autoleucel) delivered five-year treatment-free remissions in 50% of patients in early line relapsed/refractory multiple myeloma | Press Release | | | New model-based analysis further supports the potential of TECVAYLI® (teclistamab-cqyv) plus DARZALEX FASPRO® (dara…

21. #21prepared remarks

    Webcast information: Johnson & Johnson will conduct a conference call with investors to discuss this earnings release today at 8:30 a.m., Eastern Time. A simultaneous webcast of the call for investors and other interested parties may be accessed by visiting the Johnson & Johnson website . A replay and podcast will be available approximately two hours after the live webcast in the Investor Relations section of the company's website at events-and-presentations .

22. #22excluding the impact of

    Operational sales growth